Payment overview · 2025
General Payments
$198.97
11 reported records · 6 companies
Healthcare provider profile · identity verified
James Steven Robbins, DO
Allopathic & Osteopathic Physicians|Family Medicine · WEST VALLEY CITY, UT · NPI 1720234412
Verified facts
What the public records show
CMS Open Payments records show James Steven Robbins, DO received $198.97 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vraylar by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $80.57 | 40.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.25 | 22.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.07 | 10.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.68 | 10.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.94 | 8.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.46 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $198.97 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $80.57 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.25 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $45.25 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 332 | 109 |
| Omeprazole | Omeprazole | 231 | 68 |
| Lisinopril | Lisinopril | 223 | 59 |
| Metformin Hcl | Metformin Hcl | 205 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 204 | 63 |
| Trazodone Hcl | Trazodone Hcl | 163 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 145 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 26 |
| Gabapentin | Gabapentin | 133 | 46 |
| Losartan Potassium | Losartan Potassium | 132 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 130 | 17 |
| Clonazepam | Clonazepam | 113 | 15 |
| Furosemide | Furosemide | 91 | 29 |
| Meloxicam | Meloxicam | 91 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 17 |
| Montelukast Sodium | Montelukast Sodium | 88 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 24 |
| Sertraline Hcl | Sertraline Hcl | 86 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 20 |
| Ibuprofen | Ibuprofen | 83 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 26 |
| Alprazolam | Alprazolam | 80 | 12 |
| Carvedilol | Carvedilol | 79 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 69 | 24 |
| Simvastatin | Simvastatin | 68 | 19 |
| Potassium Chloride | Potassium Chloride | 67 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 15 |
| Jardiance | Empagliflozin | 49 | 14 |
| Metformin Hcl Er | Metformin Hcl | 49 | 16 |
| Pregabalin | Pregabalin | 48 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 12 |
| Linzess | Linaclotide | 45 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Estradiol | Estradiol | 43 | suppressed |
| Prednisone | Prednisone | 42 | 35 |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | 12 |
| Allopurinol | Allopurinol | 39 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 28 |
| Methocarbamol | Methocarbamol | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Glimepiride | Glimepiride | 33 | 12 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 30 | suppressed |
| Eliquis | Apixaban | 29 | 11 |
| Tramadol Hcl | Tramadol Hcl | 29 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 21 | 11 |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Dotti | Estradiol | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $198.97 · 11 records | ABBVIE INC. | AREXVY, CAPLYTA, Cologuard Collection Kit, FREESTYLE LIBRE 3, NURTEC ODT, SHINGRIX, VRAYLAR, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error